SEC Tracker
Get the app

Anavex Life Sciences AVXL

Anavex appoints Terrie Kellmeyer as CEO

Item 5.02 Executive or director change

Form
8-K
Filed
Importance
Major
  1. Dr. Kellmeyer appointed CEO and President on Nov 1, 2026
  2. Board reduced to five members, seeking new director
  3. Annual base salary remains $500,000, bonus 30% of salary

Written from the 8-K on EDGAR. Check the filing before you rely on it.

Open in the appGet the appView on EDGAR

Get an email when Anavex Life Sciences files

Only major filings: results, leadership changes, listing notices and other major events, each with the plain-English summary when we have one or the key facts and the EDGAR link. Routine insider filings never email. Confirm once; unsubscribe in one click.

The reading, claim by claim

0 of 1 claim matched the filing text.

Not found in the filing text

  • For the quarter ended June 30, 2026, ANAVEX LIFE SCIENCES CORP. reported: Net income $7.8 million.

From the filing

Item 5.02. Departure of

Item 5.02. Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain

Officers.

Appointment of Chief Executive Officer

On November 1, 2026, the Board of Directors ("Board") of Anavex

Life Sciences Corp. ("Anavex" or the "Company"), appointed Terrie Kellmeyer, Ph.D. as the Company's Chief

Executive Officer ("CEO") and President effective immediately.

Dr. Kellmeyer, age 59, has served as the Company's Interim CEO since

May 4, 2026. Dr. Kellmeyer possesses over 30 years of experience in the pharmaceutical industry and has held executive leadership positions in Clinical Development, Regulatory Affairs, Clinical Operations, and Medical Affairs across multiple therapeutic areas. Prior to her appointment as the Company's Interim CEO, she was the Senior Vice President, Clinical Development of the Company from November 2023 to May 2025 and continued to work with the Company as a Senior Advisor until her appointment as Interim CEO. Dr. Kellmeyer also served as Executive Vice President, Regulatory Affairs at Aardvark Therapeutics from May 2025 to May 2026, as a consultant at Aardvark Therapeutics from May to June 2026 and continues to serve as a Strategic Advisor to Aardvark Therapeutics. Prior to joining Anavex, Dr. Kellmeyer held strategic leadership positions, including Group Vice President of Clinical Development at Acer Therapeutics from August 2021 to November 2023, Head of Global Regulatory Affairs at Madrigal Pharmaceuticals from July 2019 to August 2021 and positions of increasing responsibility at Intercept Pharmaceuticals, Amylin Pharmaceuticals and Gen-Probe. Dr. Kellmeyer also served as a consultant to Tunnell Consulting from August 2022 to May 2026 and to i2o Therapeutics from July 2025 to December 2025. Dr. Kellmeyer received her BS degree in Biotechnology from Rochester Institute of Technology, a Ph.D. in Cell and Molecular Biology from SUNY Syracuse and completed a Post-Doctoral Fell

Item 9.01. Financial Statements and Exhibits.

Item 9.01. Financial Statements and Exhibits.

(d) Exhibits

Exhibit No.

Description

99.1

Press Release, dated November 3, 2026.

104

Cover Page Interactive Data File (embedded within the Inline XBRL document).

SIGNATURES

Pursuant to the requirements of the Securities Exchange

Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

ANAVEX LIFE SCIENCES CORP.

/s/ Sandra Boenisch

Name: Sandra Boenisch, CPA, CGA

Title: Principal Financial Officer, Treasurer

Date: November 3, 2026

Anavex Life Sciences Names Terrie Kellmeyer, Ph.D., as President and Chief Executive Officer and Member of the Board of Directors

Seasoned biopharmaceutical executive with more than 30 years of leadership experience spanning clinical development, regulatory strategy and operational execution appointed to lead company into new phase of clinical development and growth

NEW YORK, November 3, 2026 - Anavex Life Sciences Corp.

(Nasdaq: AVXL) ("Anavex" or the "Company"), a clinical-stage biopharmaceutical company developing innovative treatments for central nervous system diseases with significant unmet medical needs, today announced that on November 1, 2026, its Board of Directors appointed Terrie Kellmeyer, Ph.D., who had been serving as the Company's Interim Chief Executive Officer, as the Company's

President and Chief Executive Officer. She will also join Anavex's Board of Directors.

"Dr. Kellmeyer has provided steady leadership and a clear vision during an important period for Anavex, sharpening the focus of our clinical programs and advancing our engagement with the FDA," said Peter Donhauser, D.O., member of the Board of Directors. "She brings a deep understanding of our science, a disciplined approach to execution and an unwavering commitment to patients. The Board's decision reflects our unequivocal support for her strategy and her plans to build a top-notch management t

Similar companies

Same SIC code (2836) and public float $300M to $2B, nearest public float first, as each company reports it on its annual report cover.

  1. ImmunityBio IBRX public float $690M, Jun 30, 2025
  2. LENZ Therapeutics LENZ public float $690M, Jun 30, 2025
  3. Vir Biotechnology VIR public float $689M, Jun 30, 2025
  4. Relay Therapeutics RLAY public float $586M, Jun 30, 2025
  5. Ginkgo Bioworks Holdings DNA public float $553M, Jun 28, 2025